Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium
Claudia Pasqualini(Université Paris-Saclay), Jonathan Rubino(Université Paris-Saclay), Caroline Brard(Inserm), Lydie Cassard(Université Paris-Saclay), Nicolás André(Centre National de la Recherche Scientifique), Windy Rondof(Inserm), Jean‐Yves Scoazec(Centre National de la Recherche Scientifique), Antonin Marchais(Inserm), Souad Nebchi(Inserm), Lisa Boselli(Université Paris-Saclay), Jonathan Grivel(Université Paris-Saclay), Isabelle Aerts(Université Paris Sciences et Lettres), Estelle Thébaud(Centre Hospitalier Universitaire de Nantes), Xavier Paolettí(Inserm), Véronique Minard‐Colin(Inserm), Gilles Vassal(Université Paris-Saclay), Birgit Geoerger(Inserm)
Cited by 54Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis